Oxford Cancer Analytics

Oxford Cancer Analytics (OXcan) announced today that we have raised US$11 million in Series A funding from global investors, including in-field institutional investors in disease detection and diagnostics. With the close of this round, Dr Heinrich Roder, expert in lung cancer proteomics liquid biopsy, was appointed Senior Vice President of Research and Development at OXcan. The funding round was led by We Venture Capital and Cross-Border Impact Ventures with participation from return investors Eka Ventures, and Civilization Ventures, and new investors DigitalDx Ventures, Macmillan Cancer Support (Innovation Impact Investment Portfolio), Aurelium Ventures, OKG Capital , and prominent angel investors. This investment brings OXcan’s total funding to date to US$16.7 million, positioning the company to develop and globally commercialize a new generation of minimally invasive liquid biopsy blood tests for early cancer detection, starting from lung cancer. Concurrent with the funding round, Gemma Sturt, Senior Investment Manager at We Venture Capital (cc Louise Warme), Werfen’s Corporate Venture Arm and Annie Theriault, Managing Partner at Cross-Border Impact Ventures (cc Cyriac M Alappat CPA,CA, Donna Parr) have joined as Directors. Michele Colucci, Esq., Founder & Partner at DigitalDx Ventures and Anthony Vallance-Owen, Senior Investment Manager at We Venture Capital have joined as Observers. OXcan welcomes these experienced leaders in diagnostics, global health, and commecialization joining the board with existing members Dr Peter Jianrui Liu, Jon Coker, Marcus East, Dr Andreas Halner, and Brad Wilson. A sincere thank you to OXcan’s team members and many others who continue to drive forward early cancer detection innovation on a daily basis: Dr Daniel Szulc, Dr Ella Mi, Dr Emma M., Dr. Harriet Ferguson, Dr Honglei Huang, Dr Junetha Syed, Luke Hankey, Mrunmayee Dupalliwar, Dr Nikola I. Gushterov, Priyanka Bhattarai, and Taryn Reid. OXcan is always looking for likeminded people to help bring early cancer detection tests to those who need it most. If you want to help, please get in touch at info@oxcan.org! About Oxford Cancer Analytics Oxford Cancer Analytics is on a mission to drastically transform cancer early detection and management to impact millions of lives worldwide. OXcan's multidisciplinary team is developing a new generation of liquid biopsy blood tests using cutting-edge proteomics and explainable machine learning approaches that can detect the deadliest cancers early, when they can still be cured. This blood test can be conducted in an affordable, minimally invasive, and routine manner with superior accuracy and localization capacity in large populations. OXcan has applied their biomarker discovery and validation platform starting from lung cancer, the leading cause of cancer mortality worldwide, and achieved ISO13485 certification status. For additional information, visit oxcan.org. https://lnkd.in/evXGzFKq

Today, on World Cancer Day, we stand united in our mission to raise awareness, support research, and ultimately find solutions for the millions of people impacted by cancer worldwide. At Oxford Cancer Analytics, we are proud to be part of this collective effort, advancing the fight through innovative analytics and data-driven insights. Oxford Cancer Analytics was delighted to attend our valued partner and supporter Macmillan Cancer Support's World Cancer Day event in Westminister today featuring a timely discussion on cancer care ahead of the Government’s development of the Cancer Plan for England. Oxford Cancer Analytics continues steadfast in our mission to transform patient cancer care via blood-based early cancer detection technologies and improve patient outcomes.

Exciting News - OXcan Featured on CP24 News to Discuss $11M Series A Raise and the Future of Early Cancer Detection   We're thrilled to share that our Chief Product Officer, Dr. Daniel Szulc, sat down with Anchor Nick Dixon on CP24 News Toronto's #1 morning show to discuss Oxford Cancer Analytics $11 million USD Series A raise and how we are pioneering the future of early cancer detection through liquid biopsy and deep learning. 
Watch the interview here:
 👉 Finding Lung Cancer Early with the Help of AI
https://lnkd.in/grNyH5gx At OXcan, our mission is clear: we aim to equip clinicians with timely, accurate data that can enable earlier interventions, helping patients receive the right treatments at the right time—before it’s too late. By leveraging cutting-edge AI and liquid biopsy for early cancer detection, we can significantly improve patient outcomes and reduce the strain on healthcare systems globally. This milestone wouldn’t have been possible without the support of our amazing investors, including: • We Venture Capital • Cross-Border Impact Ventures • Eka Ventures • Civilization Ventures • DigitalDx Ventures • Macmillan Cancer Support • Aurelium Ventures • OKG Capital We are also incredibly grateful to the institutions and partners who have been with us on this journey, including: • Princess Margaret Cancer Centre, University Health Network (cc Dr. Geoffrey Liu, Devalben Patel)
 • The Francis Crick Institute KQ Labs (cc Emma Fox, Barbara Domayne-Hayman) • Creative Destruction Lab (cc William T.H. To, Sonia Sennik, Mathew Platt, Jack Norton, Chen Fong, Alexander Lazar MD/PhD, Earl Diamond, Ken Birdwell, Manish Krishnan, Anish Kirpalani, Jehangir Appoo, MD) • Canadian Cancer Society (cc Andrea Seale, Annemarie Edwards, Stuart E., Sandra Krueckl) • MaRS Discovery District (cc Nirali Rathwa, PhD, Rick Bozzato) • H2i University of Toronto (cc Neil D'Cruz, Paul Santerre, Andris Lauris) • Oxford Foundry (cc Ana Bakshi, Alex Feyler), • BioEscalator (cc Claire Shingler) • Plug and Play / Plug and Play Canada (cc Sydney Davis, Niall Kerrigan, Shahr(zad) Savizi-Smed) •  TheHill / Oxford University Hospitals NHS Foundation Trust (cc Fred Kemp) •  University of St Andrews (cc Prof Peter D Donnelly, Rishma Maini MBChB PhD FFPH, Frank Sullivan) •   And many more!
 As we enter this next exciting phase of growth, we look forward to what the future holds in our mission to transform early cancer detection. The path ahead is bright, and we are just getting started! 🚀

I’m really proud to share Macmillan Cancer Support latest investment in Oxford Cancer Analytics. 🎉 Peter Jianrui Liu & Andreas Halner have been engaging with us for several years as they’ve been building their technology. Their simple low cost and accurate blood test has the potential to make it easier to diagnose lung cancer, and to increase the number of people being tested. We couldn’t be more excited to work with them to bring this to as many people as possible. 🚀 A big thank you to the many fantastic co-investors who have made this deal possible. And in particular We Venture Capital, Cross-Border Impact Ventures and Eka Ventures. Louise Warme, Gemma Sturt, Anthony Vallance-Owen, Pooja Sikka, Cyriac M Alappat CPA,CA, Jon Coker CC the fantastic Macmillan team Tanya Humphreys, Suzuka Jomori (Matsui), Michael Stickland, Rachel Higham, Abdullahi Sheriff, David Kaye, Dawn Lee, Archie Mason, Veronique Morel-Kane Chartered FCSI, Joe Stringer 🙏

Oxford Cancer Analytics team, including Dr. Daniel Szulc , Dr. Andreas Halner , and Dr. Peter Jianrui Liu , will be attending the J.P. Morgan Healthcare Conference in San Francisco next week. Feel free to reach out to us at info@oxcan.org to connect, share insights, and discuss the future of healthcare innovation.

Thank you to Josh Scott at BetaKit for writing about our $16M CAD Series A funding round from global investors who believe in our vision for saving lives using advanced proteomics and AI. Lung cancer is the leading cause of cancer-related deaths, often because it’s detected too late. This new funding will accelerate the development and deployment of our innovations so we can empower healthcare professionals to catch lung cancer earlier—when treatment is most effective. We’re grateful to our incredible team, investors, and supporters for helping us take this critical step forward in enabling early cancer detection. Together, we’re pushing the boundaries of what’s possible in healthcare innovation. https://lnkd.in/gV2axSKU #FundingNews #HealthcareInnovation #EarlyCancerDetection #OXcan #SeriesA #LungCancer #Cancer #MedTech

What was one of the hardest things I had to do in life? Witnessing late stage cancer chip away at what remains of a close family member but not being able to help. I’ve seen the same scenario repeated with numerous patients and families I had the privilege to support throughout the years. Oxford Cancer Analytics (OXcan)’s establishment is dedicated to people and families who will fight, are fighting, and have fought cancer as a devastating disease. Today’s announcement of OXcan's US$11million series A round led by leading in-field institutional investors in disease detection and diagnostics is a testament to the progress we have made towards earlier cancer detection through developing a best-in-class blood test to enable treatments with curative intents. When OXcan started in 2020, we were a small team but a pioneer in applying advanced proteomics and tailored machine learning approaches in cancer detection among the handful of giants focusing on genomics and epigenetics in liquid biopsy. We recognized that protein-based biomarkers for early cancer detection could fill unique niches not addressable by genomic and epigenetic data. However, unlike genomic and epigenetic liquid biopsy companies that had over half a decade of head start, much more R&D was required in the field of proteomics to unleash its full potential for the development of a novel, more accurate, and affordable class of cancer detection blood test. At the same time, we recognized that although machine learning was up and coming, conventional methods were not designed to reliably analyze liquid biopsy data. Over the past 4 years, OXcan built a dedicated multidisciplinary team, proteomics & machine learning biomarker discovery platform, and large diverse international clinical cohorts from the ground up to address these hurdles. The result is a first-in-class blood test that can reliably detect lung cancer as the leading cause of cancer deaths worldwide with unprecedented accuracy and deployable with existing infrastructures in an inexpensive manner. I’m glad that experienced leaders and institutional investors agree with OXcan’s unique innovative approach in proteomics and AI. This round was co-led by We Venture Capital, Werfen & Cross-Border Impact Ventures, with participation from Eka Ventures, DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures, OKG Capital, Civilization Ventures and more! Grateful to have likeminded colleagues who supported OXcan on a road less travelled by since the early days including Brad Wilson, Marcus East, James Reynolds, Oxford Technology Management (Andrea Mica), Stephen Piron, Robin Saunders, Dr. Martin Lesourd, JJ Hodari, Benedikt Kessler, Roman Fischer, Ana Bakshi and more! These colleagues and organizations made OXcan’s ambitious but lifesaving mission possible. We still have some ways to go and we will get there! Reach out if you want to join the mission to enable early cancer detection and impact millions of lives worldwide!

How are we enabling curative treatments for cancer through a simple blood test, with protein science and AI? Oxford Cancer Analytics' CEO Dr Peter Jianrui Liu shares the latest science and a vision for the future. "The ultimate vision is to drastically transform modern disease management from a reactive to proactive approach, identifying signs of early disease development for more effective treatment and prevention. I believe we can fundamentally transform cancer detection and management to save lives and create hope for millions impacted by cancer."

Oxford Cancer Analytics was crowned the ULTIMATE WINNER at the Health Tech Challengers competition at the Health Tech Forward conference last week. Out of 400+ companies and 80 shortlisted, our President Dr Andreas Halner pitched over selection rounds and in the final of 8 companies, winning 1st place. Andreas Halner showcased Oxford Cancer Analytics's mission to transform cancer management and care, shifting the paradigm away from the current reality of the majority of the deadliest cancers being detected too late to a new world where early detection can enable curative treatment. Oxford Cancer Analytics' leading innovations in the field of early cancer detection, proteomics, and explainable AI culminating in a scalable blood test solution begin with lung cancer, the biggest cancer killer worldwide. Join Oxford Cancer Analytics on a mission to positively transform the lives of millions of patients and their families around the globe!

🌟 OXcan at the Lung Cancer Summit Toronto 🌟 Last week, Oxford Cancer Analytics had the honor of attending and sharing our mission at the Lung Cancer Summit in Toronto, joining a passionate and diverse group of individuals, including patients, caregivers, clinicians, researchers, health charities, and government representatives. All were united by one goal: improving lung cancer care in Canada. Dr. Peter Jianrui Liu and Dr. Daniel Szulc were proud to contribute to discussions shaping the Pan-Canadian Lung Cancer Action Plan, a vital initiative aiming to address the challenges in lung cancer treatment and care. Lung cancer remains the leading cause of cancer-related death in Canada, and while we’ve made progress, there’s still much work ahead. The Canadian Cancer Society (CCS), in partnership with patient organizations and individuals with lived experience, is set to launch this collaborative plan in 2025. It was truly inspiring to work alongside so many dedicated individuals and organizations, including:  Annemarie Edwards, Christian Finley, Sandra Krueckl, Senator & Elder Margaret Bear, Angus Pratt, Ambreen Sayani, Vinesha Ramasamy, Lisa Roelfsema, Desirée Hao, Ojistoh Horn, Shift Health, Dr. Stephen Lam, Robin Urquhart, Kazuhiro Yasufuku, Natasha Leighl, and more. Together, we are paving the way for a brighter future in lung cancer care.